|
Jun 29
|
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
|
|
Jun 29
|
This Psychedelic Drug Flopped on Trial Results. Should You Buy the Dip?
|
|
Jun 27
|
Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial
|
|
Mar 18
|
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression
|
|
Mar 11
|
Compass Pathways to Participate in Stifel Virtual CNS Forum
|
|
Feb 18
|
Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
|
|
Dec 18
|
Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)
|